Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review.
PURPOSE: The effectiveness of immunotherapy for postoperative hepatocellular carcinoma patients is still controversial. To address this issue, we did a systemic review of the literatures and analyzed the data with emphasis on the recurrence and survival. METHODS: We searched six randomized controlle...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3419734?pdf=render |
id |
doaj-919dcdb480284dbd93fa6c22e1f1fd88 |
---|---|
record_format |
Article |
spelling |
doaj-919dcdb480284dbd93fa6c22e1f1fd882020-11-25T02:57:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0178e4287910.1371/journal.pone.0042879Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review.Feng XieXinji ZhangHui LiTao ZhengFeng XuRongxi ShenLong YanJiamei YangJia HePURPOSE: The effectiveness of immunotherapy for postoperative hepatocellular carcinoma patients is still controversial. To address this issue, we did a systemic review of the literatures and analyzed the data with emphasis on the recurrence and survival. METHODS: We searched six randomized controlled trials that included adoptive immunotherapy in the postoperative management of hepatocellular carcinoma and compared with non-immunotherapy postoperation. A meta-analysis was carried out to examine one- and 3-year recurrence and survival. RESULTS: The overall analysis revealed significantly reduced risk of 1-year recurrence in patients receiving adoptive immunotherapy (OR=0.35; 95% CI, 0.17 to 0.71; p=0.003), in that the risk of 3-year recurrence with a pooled OR estimated at 0.31 (95% CI 0.16 to 0.61; p=0.001). However, no statistically significant difference was observed for 3-year survival between groups with adoptive immunotherapy and without adjuvant treatment (OR=0.91; 95% CI, 0.45 to 1.84; P=0.792). CONCLUSIONS: Adjuvant immunotherapy with cytokine induced killer cells or lymphokine activated killer cells may reduce recurrence in postoperative hepatocellular carcinoma patients, but may not improve survival.http://europepmc.org/articles/PMC3419734?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Feng Xie Xinji Zhang Hui Li Tao Zheng Feng Xu Rongxi Shen Long Yan Jiamei Yang Jia He |
spellingShingle |
Feng Xie Xinji Zhang Hui Li Tao Zheng Feng Xu Rongxi Shen Long Yan Jiamei Yang Jia He Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS ONE |
author_facet |
Feng Xie Xinji Zhang Hui Li Tao Zheng Feng Xu Rongxi Shen Long Yan Jiamei Yang Jia He |
author_sort |
Feng Xie |
title |
Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
title_short |
Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
title_full |
Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
title_fullStr |
Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
title_full_unstemmed |
Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
title_sort |
adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
PURPOSE: The effectiveness of immunotherapy for postoperative hepatocellular carcinoma patients is still controversial. To address this issue, we did a systemic review of the literatures and analyzed the data with emphasis on the recurrence and survival. METHODS: We searched six randomized controlled trials that included adoptive immunotherapy in the postoperative management of hepatocellular carcinoma and compared with non-immunotherapy postoperation. A meta-analysis was carried out to examine one- and 3-year recurrence and survival. RESULTS: The overall analysis revealed significantly reduced risk of 1-year recurrence in patients receiving adoptive immunotherapy (OR=0.35; 95% CI, 0.17 to 0.71; p=0.003), in that the risk of 3-year recurrence with a pooled OR estimated at 0.31 (95% CI 0.16 to 0.61; p=0.001). However, no statistically significant difference was observed for 3-year survival between groups with adoptive immunotherapy and without adjuvant treatment (OR=0.91; 95% CI, 0.45 to 1.84; P=0.792). CONCLUSIONS: Adjuvant immunotherapy with cytokine induced killer cells or lymphokine activated killer cells may reduce recurrence in postoperative hepatocellular carcinoma patients, but may not improve survival. |
url |
http://europepmc.org/articles/PMC3419734?pdf=render |
work_keys_str_mv |
AT fengxie adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT xinjizhang adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT huili adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT taozheng adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT fengxu adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT rongxishen adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT longyan adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT jiameiyang adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview AT jiahe adoptiveimmunotherapyinpostoperativehepatocellularcarcinomaasystemicreview |
_version_ |
1724711603405848576 |